文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克3.0定义与试验:血管加压素与脓毒性休克试验的经验

The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论在血管加压素与脓毒性休克试验的回顾性分析中,若采用脓毒性休克3.0定义(乳酸>2 mmol/L)会使样本量减半、28天死亡率升高约10%,且仅在乳酸≤2 mmol/L亚组中血管加压素较去甲肾上腺素降低死亡率。

该研究是对血管加压素与脓毒性休克试验的回顾性分析,比较了乳酸≤2 mmol/L与>2 mmol/L两个亚组中血管加压素(0.03 U/min)与去甲肾上腺素的疗效差异,并检测了39种细胞因子。结果显示,采用脓毒性休克3.0定义会使样本量减半,28天和90天死亡率比原试验高10-12%;在乳酸≤2 mmol/L亚组中血管加压素组死亡率显著低于去甲肾上腺素组(p=0.028),而乳酸>2 mmol/L亚组两组无差异;乳酸>2 mmol/L组几乎所有细胞因子水平均显著高于乳酸≤2 mmol/L组。作者认为这些发现对脓毒性休克试验设计有重要意义。

要点

  • 在乳酸≤2 mmol/L亚组中,血管加压素(0.03 U/min)较去甲肾上腺素显著降低死亡率(p=0.028);乳酸>2 mmol/L亚组两组无差异。
  • 采用脓毒性休克3.0定义(乳酸>2 mmol/L)会使试验样本量减半,28天和90天死亡率比原试验高10-12%。
  • 乳酸>2 mmol/L患者几乎所有细胞因子水平均显著高于乳酸≤2 mmol/L患者,提示对感染的细胞因子反应更剧烈。
  • 作者认为脓毒性休克3.0定义及本研究发现对脓毒性休克试验设计有重要影响。

适用人群与场景

  • 脓毒性休克患者,按乳酸>2 mmol/L或≤2 mmol/L分组,随机接受血管加压素或去甲肾上腺素。

诊断标准与关键阈值

  • 脓毒性休克3.0定义:乳酸>2 mmol/L。

处置流程与药物剂量

  • 血管加压素0.03 U/min静脉输注( concealed infusion),或去甲肾上腺素输注。

研究设计与关键结果

  • 研究类型:随机对照试验的回顾性分析;场所:多中心ICU;人群:脓毒性休克患者,随机接受血管加压素(0.03 U/min)或去甲肾上腺素。
  • 采用脓毒性休克3.0定义会使样本量减少约一半;28天和90天死亡率比原血管加压素与脓毒性休克试验高10-12%。
  • 在乳酸≤2 mmol/L亚组中,血管加压素组死亡率显著低于去甲肾上腺素组(p=0.028);在乳酸>2 mmol/L亚组中,两组治疗无差异。
  • 乳酸>2 mmol/L组几乎所有细胞因子水平均显著高于乳酸≤2 mmol/L组。

证据类型、等级与局限

  • 证据类型:随机对照试验的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为脓毒性休克3.0定义及本研究发现对脓毒性休克试验设计有重要影响。
  • 在乳酸≤2 mmol/L的脓毒性休克患者中,血管加压素较去甲肾上腺素降低死亡率;在乳酸>2 mmol/L患者中两组无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The Septic Shock 3.0 definition could alter treatment comparisons in randomized controlled trials in septic shock. Our first hypothesis was that the vasopressin versus norepinephrine comparison and 28-day mortality of patients with Septic Shock 3.0 definition (lactate > 2 mmol/L) differ from vasopressin versus norepinephrine and mortality in Vasopressin and Septic Shock Trial. Our second hypothesis was that there are differences in plasma cytokine levels in Vasopressin and Septic Shock Trial for lactate less than or equal to 2 versus greater than 2 mmol/L.

DESIGN: Retrospective analysis of randomized controlled trial.

SETTING: Multicenter ICUs.

METHODS: We compared vasopressin-to-norepinephrine group 28- and 90-day mortality in Vasopressin and Septic Shock Trial in lactate subgroups. We measured 39 cytokines to compare patients with lactate less than or equal to 2 versus greater than 2 mmol/L.

PATIENTS: Patients with septic shock with lactate greater than 2 mmol/L or less than or equal to 2 mmol/L, randomized to vasopressin or norepinephrine.

INTERVENTIONS: Concealed vasopressin (0.03 U/min.) or norepinephrine infusions.

MEASUREMENTS AND MAIN RESULTS: The Septic Shock 3.0 definition would have decreased sample size by about half. The 28- and 90-day mortality rates were 10-12 % higher than the original Vasopressin and Septic Shock Trial mortality. There was a significantly (p = 0.028) lower mortality with vasopressin versus norepinephrine in lactate less than or equal to 2 mmol/L but no difference between treatment groups in lactate greater than 2 mmol/L. Nearly all cytokine levels were significantly higher in patients with lactate greater than 2 versus less than or equal to 2 mmol/L.

CONCLUSIONS: The Septic Shock 3.0 definition decreased sample size by half and increased 28-day mortality rates by about 10%. Vasopressin lowered mortality versus norepinephrine if lactate was less than or equal to 2 mmol/L. Patients had higher plasma cytokines in lactate greater than 2 versus less than or equal to 2 mmol/L, a brisker cytokine response to infection. The Septic Shock 3.0 definition and our findings have important implications for trial design in septic shock.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Russell JA, Lee T, Singer J, et al. The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience. Crit Care Med. 2017. PMID: 28333757. doi:10.1097/CCM.0000000000002323

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。